Home/Xeris Biopharma/Kenneth E. Johnson

KE

Kenneth E. Johnson

Chief Commercial Officer

Xeris Biopharma

Therapeutic Areas

Endocrinology Neurology Cardiology

Xeris Biopharma Pipeline

Drug	Indication	Phase
Gvoke	Severe Hypoglycemia (Diabetes)	Commercial
Keveyis	Primary Periodic Paralyses	Commercial
Recorlev	Endogenous Cushing’s Syndrome	Commercial
XP-8121	Undisclosed Neurological Indication	Preclinical
XP-19986	Undisclosed Cardiovascular Indication	Preclinical

Leadership Team at Xeris Biopharma

Chairman and Chief Executive Officer

Barry M. Deutsch

Chief Financial Officer

Chief Development Officer

Steven Prestrelski

Chief Scientific Officer and Co-founder

Chief Legal Officer and Corporate Secretary

View full Xeris Biopharma profile